Skip to main content

Table 2 Axillary response following NST

From: Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype

Characteristic

All patients (n = 69)

ER+/HER2- (n = 33)

HER2+ (n = 16)

TN (n = 20)

p-value

All patients

Axillary response

    

0.001a

 Axillary residual

32 (46.4%)

22 (66.7%)

2 (12.5%)

8 (40.0%)

 No axillary residual

37 (53.6%)

11 (33.3%)

14 (87.5%)

12 (60.0%)

Clinically node-positive patients

Axillary response

    

0.014a

 Axillary residual

27 (51.9%)

17 (68.0%)

2 (16.7%)

8 (53.3%)

 Axillary pCR

25 (48.1%)

8 (32.0%)

10 (83.3%)

7 (46.7%)

  1. ER, estrogen receptor; HER2, human epidermal growth factor 2 receptor; pCR, pathologic complete response
  2. aPearsons’ chi-square test; all variables are displayed as number and percentage